PROFIL RESISTENSI ANTIRETROVIRAL PADA PASIEN HIV/AIDS DI RSUD Dr. SOETOMO SURABAYA
Background: Dr. Soetomo Surabaya general hospital is a referral hospitals in the eastern part of Indonesia. Many HIV/AIDS patients were treated in hospital, so it needs to investigated the profile of ARV resistance. Objectives: The objective of this study was to identify the profile of ARV resist...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses and Dissertations NonPeerReviewed |
| Language: | Indonesian Indonesian Indonesian Indonesian |
| Published: |
2018
|
| Subjects: | |
| Online Access: | http://repository.unair.ac.id/84774/1/FK.PD.%2045-19%20Pra%20p%20Abstrak.pdf http://repository.unair.ac.id/84774/2/FK.PD.%2045-19%20Pra%20p%20Daftar%20Isi.pdf http://repository.unair.ac.id/84774/3/FK.PD.%2045-19%20Pra%20p%20Daftar%20Pustaka.pdf http://repository.unair.ac.id/84774/4/FK.PD.%2045-19%20Pra%20p.pdf http://repository.unair.ac.id/84774/ http://lib.unair.ac.id |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Universitas Airlangga |
| Language: | Indonesian Indonesian Indonesian Indonesian |
| Summary: | Background: Dr. Soetomo Surabaya general hospital is a referral hospitals in the
eastern part of Indonesia. Many HIV/AIDS patients were treated in hospital, so it needs
to investigated the profile of ARV resistance.
Objectives: The objective of this study was to identify the profile of ARV resistance
in treated patients in Dr. Soetomo general hospital.
Method: This study was using descriptive – retrospective design. The data of the
profile ARV resistance was obtained for treated patients by using medical record.
Result: Lamivudine and Nevirapine most often used, the most combination given was
Lamivudine + Zidovudine + Nevirapine, the most resistant in Nevirapine and
Efavirenz, based on the polymerase region mutase pattern of the NNRTI drug group
was in Nevirapine (Y181C 50%) and Efavirenz (V106M 20%) while the NRTI group
was in Lamivudine (M184V 12%) and Tenofovir (K65R 6%).
Conclusion: Most patients have resistance to Nevirapine and Efavirenz, NNRTI
groups on Nevirapine drugs obtained a Y181C, V108I, V106I, G190GA mutation of
47%, whereas in Efavirenz Y181C, V108I, V106I mutations were 41.2%. And from
the NRTI group on the Lamivudine drug M184V was obtained, K65R was 29.4%, the
Emitricitabine drug was M184V, K65R was 29.4%, Tenofovir was K65R was 11.8%,
and Zidovudine was K219QE of 5.9%. |
|---|